Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 11/2004

01-11-2004 | Article

IgG4-subclass of glutamic acid decarboxylase antibody is more frequent in latent autoimmune diabetes in adults than in type 1 diabetes

Authors: M. Hillman, C. Törn, H. Thorgeirsson, M. Landin-Olsson

Published in: Diabetologia | Issue 11/2004

Login to get access

Abstract

Aims/hypothesis

Glutamic acid decarboxylase autoantibodies (GADA) are the most frequent beta-cell-specific autoantibodies in type 1 diabetes and in latent autoimmune diabetes in adults (LADA). The autoimmune attack on pancreatic islet cells is associated with a T helper 1 cell (Th1) response, mainly represented by IgG1-subclass in humans. It has been proposed that the presence of IgG4 may be associated with a Th2 response. The aim of our study was to compare the GADA IgG-subclass distribution between adult patients with type 1 diabetes and LADA.

Methods

Patients with type 1 diabetes (n=45) and patients with LADA (n=60) were included. Radioimmunoprecipitation assay with IgG-subclass specific Sepharose (IgG1, IgG2, IgG3 and IgG4) was used to precipitate the antibody/antigen-complex.

Results

We only detected IgG4-subclass of GADA in subjects with LADA (26.7%; p<0.001). IgG1 was the most common GADA-subclass in both groups, however IgG1 as the solely expressed subclass was more common among type 1 diabetic patients (77.8%; p<0.05). The rank order of the frequencies of IgG-subclasses in type 1 diabetes was IgG1>IgG3>IgG2>IgG4 and in LADA patients IgG1>IgG4>IgG2>IgG3.

Conclusions/interpretation

The difference in GADA IgG-subclasses could indicate a different immune response, possibly an altered balance between Th1 and Th2 cytokine profile in pancreatic islets. This difference could contribute to the slower rate of beta cell destruction in LADA patients, as reflected by a higher C-peptide level at clinical onset.
Literature
1.
Törn C, Landin-Olsson M, Östman J et al. (2000) Glutamic acid decarboxylase antibodies (GADA) is the most important factor for prediction of insulin therapy within 3 years in young adult diabetic patients not classified as Type 1 diabetes on clinical grounds. Diabetes Metab Res Rev 16:442–447CrossRefPubMed
2.
Carlsson A, Sundkvist G, Groop L, Tuomi T (2000) Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA). J Clin Endocrinol Metab 85:76–80CrossRefPubMed
3.
Törn C, Gupta M, Nikitina Zake L, Sanjeevi CB, Landin-Olsson M (2003) Heterozygosity for MICA5.0/MICA5.1 and HLA-DR3-DQ2/DR4-DQ8 are independent genetic risk factors for latent autoimmune diabetes in adults. Hum Immunol 64:902–909CrossRefPubMed
4.
Tuomi T, Carlsson A, Li H et al. (1999) Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes 48:150–157PubMed
5.
Hagopian WA, Sanjeevi CB, Kockum I et al. (1995) Glutamate decarboxylase-, insulin-, and islet cell-antibodies and HLA typing to detect diabetes in a general population-based study of Swedish children. J Clin Invest 95:1505–1511PubMed
6.
Turner R, Stratton I, Horton V et al. (1997) UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 350:1288–1293CrossRefPubMed
7.
Bonifacio E, Scirpoli M, Kredel K, Fuchtenbusch M, Ziegler AG (1999) Early autoantibody responses in prediabetes are IgG1 dominated and suggest antigen-specific regulation. J Immunol 163:525–532PubMed
8.
Couper JJ, Harrison LC, Aldis JJ, Colman PG, Honeyman MC, Ferrante A (1998) IgG subclass antibodies to glutamic acid decarboxylase and risk for progression to clinical insulin-dependent diabetes. Hum Immunol 59:493–499CrossRefPubMed
9.
Schmid S, Molteni A, Fuchtenbusch M, Naserke HE, Ziegler AG, Bonifacio E (2002) Reduced IL-4 associated antibody responses to vaccine in early pre-diabetes. Diabetologia 45:677–685CrossRefPubMed
10.
Hawa MI, Fava D, Medici F et al. (2000) Antibodies to IA-2 and GAD65 in type 1 and type 2 diabetes: isotype restriction and polyclonality. Diabetes Care 23:228–233PubMed
11.
Koczwara K, Schenker M, Schmid S, Kredel K, Ziegler AG, Bonifacio, E (2003) Characterization of antibody responses to endogenous and exogenous antigen in the nonobese diabetic mouse. Clin Immunol 106:155–162CrossRefPubMed
12.
Mosmann TR, Sad S (1996) The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17:138–146CrossRefPubMed
13.
Petersen JS, Kulmala P, Clausen JT, Knip M, Dyrberg T (1999) Progression to Type 1 diabetes is associated with a change in the immunoglobulin isotype profile of autoantibodies to glutamic acid decarboxylase (GAD65). Childhood Diabetes in Finland Study Group. Clin Immunol 90:276–281CrossRefPubMed
14.
15.
Grubin CE, Daniels T, Toivola B et al. (1994) A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia 37:344–350CrossRefPubMed
16.
Verge CF, Stenger D, Bonifacio E et al. (1998) Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in Type 1 diabetes: Combinatorial Islet Autoantibody Workshop. Diabetes 47:1857–1866PubMed
17.
Törn C, Landin-Olsson M, Scherstén B (2001) Predictability of C-peptide for autoimmune diabetes in young adult diabetic patients. Pract Diab Int 18:83–88CrossRef
18.
Seissler J, Eikamp K, Schott M, Scherbaum WA (2002) IA-2 autoantibodies restricted to the IgG4 subclass are associated with protection from Type 1 diabetes. Horm Metab Res 34:186–191CrossRefPubMed
19.
Ng WY, Lui KF, Cheah JS, Thai AC (2002) IgG1 subclass dominates autoimmune response to tyrosine phosphatase-like molecule IA-2 in Chinese Type 1 diabetes patients. Horm Metab Res 34:596–600CrossRefPubMed
20.
Kero J, Gissler M, Hemminki E, Isolauri E (2001) Could TH1 and TH2 diseases coexist? Evaluation of asthma incidence in children with coeliac disease, Type 1 diabetes, or rheumatoid arthritis: a register study. J Allergy Clin Immunol 108:781–783CrossRefPubMed
21.
Ng WY, Thai AC, Lui KF, Yeo PP, Cheah JS (1999) Systemic levels of cytokines and GAD-specific autoantibodies isotypes in Chinese IDDM patients. Diabetes Res Clin Pract 43:127–135CrossRefPubMed
22.
Kasuga A, Shimada A, Ozawa Y, Maruyama T, Oya K, Saruta T (2000) IgG1 is the dominant subclass of antibody against glutamic acid decarboxylase among Type 1 diabetes in Japanese. Endocr J 47:57–62PubMed
23.
Rook G (2001) Th1- or Th2-cell commitment during infectious disease: an oversimplification? Trends Immunol 22:481–482CrossRefPubMed
24.
Sheikh A, Smeeth L, Hubbard R (2003) There is no evidence of an inverse relationship between TH2-mediated atopy and TH1-mediated autoimmune disorders: Lack of support for the hygiene hypothesis. J Allergy Clin Immunol 111:131–135CrossRefPubMed
25.
Feili-Hariri M, Falkner DH, Gambotto A et al. (2003) Dendritic cells transduced to express interleukin-4 prevent diabetes in nonobese diabetic mice with advanced insulitis. Hum Gene Ther 14:13–23CrossRefPubMed
26.
Yang Z, Chen M, Wu R et al. (2002) Suppression of autoimmune diabetes by viral IL-10 gene transfer. J Immunol 168:6479–6485PubMed
27.
Cameron MJ, Arreaza GA, Zucker P et al. (1997) IL-4 prevents insulitis and insulin-dependent diabetes mellitus in nonobese diabetic mice by potentiation of regulatory T helper-2 cell function. J Immunol 159:4686–4692PubMed
28.
Kukreja A, Maclaren NK (2000) Current cases in which epitope mimicry is considered as a component cause of autoimmune disease: immune-mediated (type 1) diabetes. Cell Mol Life Sci 57:534–541PubMed
29.
Petrovsky N, Silva D, Schatz D (2003) Vaccine therapies for the prevention of Type 1 diabetes mellitus. Paediatr Drugs 5:575–582PubMed
Metadata
Title
IgG4-subclass of glutamic acid decarboxylase antibody is more frequent in latent autoimmune diabetes in adults than in type 1 diabetes
Authors
M. Hillman
C. Törn
H. Thorgeirsson
M. Landin-Olsson
Publication date
01-11-2004
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 11/2004
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1558-5

Other articles of this Issue 11/2004

Diabetologia 11/2004 Go to the issue

Article

Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: prevention of diabetes and ectopic lipid deposition

Article

Reduction of beta cell mass: partial insulin secretory compensation from the residual beta cell population in the nicotinamide–streptozotocin Göttingen minipig after oral glucose in vivo and in the perfused pancreas

Authors’ Reply

Reply to Comment on: Ong KK, Petry CJ, Emmett PM et al.; ALSPAC study team (2004) Insulin sensitivity and secretion in normal children related to size at birth, postnatal growth, and plasma insulin-like growth factor-I levels. Diabetologia 47:1064–1070

Article

Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy

Short Communication

Smoking is associated with an increased risk of type 2 diabetes but a decreased risk of autoimmune diabetes in adults: an 11-year follow-up of incidence of diabetes in the Nord-Trøndelag study

Article

Type 2 diabetes mellitus is associated with increased axial bone density in men and women from the Hertfordshire Cohort Study: evidence for an indirect effect of insulin resistance?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits